Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

611 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of wound microbes in epidermolysis bullosa: A focus on Pseudomonas aeruginosa.
Scollan ME, Levin LE, Lucky AW, Hook KP, Peoples K, Bruckner AL, Feinstein JA, Pope E, McCuaig CC, Powell J, Eichenfield LF, Levy ML, Diaz L, Glick SA, Paller AS, Browning JC, Morel KD. Scollan ME, et al. Among authors: paller as. Pediatr Dermatol. 2023 Sep-Oct;40(5):863-865. doi: 10.1111/pde.15383. Epub 2023 Jun 26. Pediatr Dermatol. 2023. PMID: 37364926
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort.
Abuabara K, Eichenfield LF, Bissonnette R, Silverberg JI, Bagel J, Guttman-Yassky E, Thaci D, Simpson EL, Harris JE, Krueger J, Myers DE, Gamelli A, Milutinovic M, Parneix A, Crawford JM, Hildebrand JS, Munoz B, Paller AS. Abuabara K, et al. Among authors: paller as. J Am Acad Dermatol. 2023 Aug;89(2):345-347. doi: 10.1016/j.jaad.2022.08.065. Epub 2022 Dec 13. J Am Acad Dermatol. 2023. PMID: 36521798 No abstract available.
Assessing pain catastrophizing and functional disability in pediatric epidermolysis bullosa patients.
Rangu S, Collins J, García-Romero MT, Augsburger BD, Bruckner AL, Diaz LZ, Eichenfield LF, Faig W, Gorell ES, Lefferdink R, Lucky AW, Morel KD, Paller AS, Park H, Pastrana-Arellano E, Peoples K, Wiss K, Perman MJ, Castelo-Soccio L. Rangu S, et al. Among authors: paller as. Pediatr Dermatol. 2023 May-Jun;40(3):422-427. doi: 10.1111/pde.15220. Epub 2022 Dec 29. Pediatr Dermatol. 2023. PMID: 36579717 Free PMC article.
Development and Validation of the Morphea Activity Measure in Patients With Pediatric Morphea.
García-Romero MT, Tollefson M, Pope E, Brandling-Bennett HA, Paller AS, Keimig E, Arkin L, Wanat KA, Humphrey SR, Werth VP, Oza V, Jacobe H, Fett N, Cordoro KM, Medina-Vera I, Chiu YE. García-Romero MT, et al. Among authors: paller as. JAMA Dermatol. 2023 Mar 1;159(3):299-307. doi: 10.1001/jamadermatol.2022.6365. JAMA Dermatol. 2023. PMID: 36753150 Free PMC article.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis.
Jacobson ME, Myles IA, Paller AS, Eichenfield LF, Simpson EL. Jacobson ME, et al. Among authors: paller as. Dermatology. 2024;240(1):85-94. doi: 10.1159/000532054. Epub 2023 Aug 14. Dermatology. 2024. PMID: 37579728 Clinical Trial.
Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.
Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Sidbury R. Davis DMR, et al. Among authors: paller as. J Am Acad Dermatol. 2024 Feb;90(2):342-345. doi: 10.1016/j.jaad.2023.08.103. Epub 2023 Nov 7. J Am Acad Dermatol. 2024. PMID: 37943241
In-person validation of the Ichthyosis Scoring System.
Echeandia-Francis C, Sun Q, Asch S, Bayart C, Benjamin L, Cipriano SD, Craiglow B, Dyer J, Levy ML, Lilly E, Newell B, Liang J, Gan G, Deng Y, Paller AS, Choate KA. Echeandia-Francis C, et al. Among authors: paller as. Pediatr Dermatol. 2024 Mar-Apr;41(2):247-252. doi: 10.1111/pde.15508. Epub 2024 Jan 17. Pediatr Dermatol. 2024. PMID: 38234066
Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
Paller AS, Seyger MMB, Magariños GA, Pinter A, Cather JC, Rodriguez-Capriles C, Zhu D, Somani N, Garrelts A, Papp KA; IXORA-PEDS Investigators. Paller AS, et al. JAMA Dermatol. 2022 May 1;158(5):533-541. doi: 10.1001/jamadermatol.2022.0655. JAMA Dermatol. 2022. PMID: 35416908 Free PMC article. Clinical Trial.
611 results